Loading
By reading 21 breast cancer genomes deeply, researchers showed that most of a tumour's mutations are carried by only some of its cells, and that every tumour had a dominant branch.
The abstract reports that subclonal diversification is prominent, that most mutations are found in just a fraction of tumour cells, and that every tumour has a dominant subclonal lineage representing more than 50 per cent of tumour cells. The full text states that subclonal point mutations were found in all samples studied and that their estimated number genome-wide was, for most samples, more than the number of fully clonal mutations. One ER-positive tumour with a distinctive mutator pattern was sequenced to 188-fold depth to find low-fraction mutations: 70,690 somatic substitutions, many supported by fewer than 5 per cent of reads, including a cluster of about 15,600 found in about 65 per cent of tumour cells.
Breast cancers are not short of subclonal mutations; they are hard to find without deep sequencing of the tumour, and residual disease panels that keep only high-fraction mutations leave them out.
Shares Cell, Naming which clone or phenotype is left after treatment, Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
Shares Naming which clone or phenotype is left after treatment, Whole-exome & whole-genome sequencing, Breast cancer (all types).
Shares Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
Shares Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
Shares Naming which clone or phenotype is left after treatment, Breast cancer (all types).
Shares Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
Shares Naming which clone or phenotype is left after treatment, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/